Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trialOrnella Verrastro, Geltrude Mingrone, Maria Assunta Zocco et al.|The Lancet|2023Cited by 338
Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic SurgeryMaria Francesca Russo, Geltrude Mingrone, Erminia Lembo et al.|The Journal of Clinical Endocrinology & Metabolism|2020Cited by 27
Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetesErminia Lembo, Esmeralda Capristo, Maria Francesca Russo et al.|Diabetes & Metabolism|2022Cited by 22
Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesityGiulia Angelini, Geltrude Mingrone, Lidia Castagneto‐Gissey et al.|American Journal of Physiology-Gastrointestinal and Liver Physiology|2020Cited by 14
Dodecanedioic acid prevents and reverses metabolic‐associated liver disease and obesity and ameliorates liver fibrosis in a rodent model of diet‐induced obesityGiulia Angelini, Geltrude Mingrone, Sara Russo et al.|The FASEB Journal|2024Cited by 8